Aerie Pharmaceuticals’ AR-15512: Promising Results in Dry Eye Treatment Study

Aerie Pharmaceuticals Inc ((AERI)) announced an update on their ongoing clinical study.

Aerie Pharmaceuticals Inc. recently completed a Phase 3 study titled A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2). The study aimed to assess the safety and effectiveness of AR-15512, a new treatment for dry eye disease, which is a common condition that affects millions globally. The study’s significance lies in its potential to offer a new therapeutic option for patients suffering from this condition.

The intervention being tested is AR-15512, an experimental ophthalmic solution designed to modulate cold thermoreceptors in the eye, potentially providing relief from dry eye symptoms. The treatment involves administering one drop of 0.003% AR-15512 in each eye twice daily for 90 days.

This interventional study was randomized and double-masked, meaning neither the participants nor the investigators knew who received the actual drug or the placebo. The primary purpose was treatment, with participants randomly assigned to either the AR-15512 group or a placebo group in a parallel intervention model.

The study began on May 9, 2022, and reached primary completion on July 16, 2024. The results were first submitted on June 2, 2025, and the last update was on July 22, 2025. These dates are crucial as they mark the study’s progression and the availability of its findings.

The completion of this study could have significant market implications for Aerie Pharmaceuticals, now a part of Alcon, as positive results may boost investor confidence and potentially impact stock performance. In the competitive landscape of dry eye treatments, successful outcomes could position AR-15512 as a strong contender.

The study is completed, with further details available on the ClinicalTrials portal.